Mitigation of pre-existing immunogenicity in ADA method development
Preexisting, immunoglobulin-mediated reactivity targeting ALXN-X's Cterminal framework sequence complicates ADA assay performance. A modified ADA assay mitigates this interference while preserving detection of ALXN-X-specific ADA, supporting more reliable immunogenicity assessment.
Authors
- Praveen K. Amancha (ORCID: https://orcid.org/0000-0001-6466-8112)
- Chris Gardner
- Jihua Chen
- Ryan Pelto
- Meng Chen
- Henry Zhao
- Jianquan Wang
- Ming Li
- Manoj Rajadhyaksha
Institutions
- Alexion Pharmaceuticals (United States) (US)
- Alexion Pharma (Switzerland) (CH)
Publication Details
- Journal
- Bioanalysis
- Published
- 2026-01-02
- DOI
- https://doi.org/10.1080/17576180.2026.2623034
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00